These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 22775758)

  • 1. Overview of metformin: special focus on metformin extended release.
    Ali S; Fonseca V
    Expert Opin Pharmacother; 2012 Aug; 13(12):1797-805. PubMed ID: 22775758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of once- or twice-daily extended release metformin compared with thrice-daily immediate release metformin in type 2 diabetes mellitus.
    Bhansali A; Masoodi SR
    J Assoc Physicians India; 2005 May; 53():441-5. PubMed ID: 16124352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advantages of extended-release metformin in patients with type 2 diabetes mellitus.
    Jabbour S; Ziring B
    Postgrad Med; 2011 Jan; 123(1):15-23. PubMed ID: 21293080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort study.
    Blonde L; Dailey GE; Jabbour SA; Reasner CA; Mills DJ
    Curr Med Res Opin; 2004 Apr; 20(4):565-72. PubMed ID: 15119994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical development of metformin extended-release tablets for type 2 diabetes: an overview.
    Schwartz SL; Gordi T; Hou E; Cramer M; Heritier M; Cowles VE
    Expert Opin Drug Metab Toxicol; 2008 Sep; 4(9):1235-43. PubMed ID: 18721117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolving metformin treatment strategies in type-2 diabetes: from immediate-release metformin monotherapy to extended-release combination therapy.
    Chacra AR
    Am J Ther; 2014; 21(3):198-210. PubMed ID: 22314210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose Comparison And Side Effect Profile Of Metformin Extended Release Versus Metformin Immediate Release.
    Hameed M; Khan K; Salman S; Mehmood N
    J Ayub Med Coll Abbottabad; 2017; 29(2):225-229. PubMed ID: 28718236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Saxagliptin/metformin (kombiglyze XR) for type 2 diabetes.
    Med Lett Drugs Ther; 2011 Mar; 53(1360):21-2. PubMed ID: 21412207
    [No Abstract]   [Full Text] [Related]  

  • 9. Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus.
    Guarino E; Nigi L; Patti A; Fondelli C; Dotta F
    Expert Opin Pharmacother; 2012 Jun; 13(9):1377-84. PubMed ID: 22397507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Saxagliptin and metformin XR combination therapy provides glycemic control over 24 hours in patients with T2DM inadequately controlled with metformin.
    Stenlöf K; Raz I; Neutel J; Ravichandran S; Berglind N; Chen R
    Curr Med Res Opin; 2010 Oct; 26(10):2355-63. PubMed ID: 20804445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rosiglitazone maleate + metformin hydrochloride extend: review of an emerging compound.
    Cheng AY; Josse RG
    Expert Opin Investig Drugs; 2009 Sep; 18(9):1365-73. PubMed ID: 19642952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metformin extended release--DepoMed: metformin, metformin gastric retention, metformin GR.
    Drugs R D; 2004; 5(4):231-3. PubMed ID: 15230631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term efficacy of metformin therapy in nonobese individuals with type 2 diabetes.
    Ong CR; Molyneaux LM; Constantino MI; Twigg SM; Yue DK
    Diabetes Care; 2006 Nov; 29(11):2361-4. PubMed ID: 17065668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The metabolic effects of once daily extended-release metformin in patients with type 2 diabetes: a multicentre study.
    Gao H; Xiao W; Wang C; Zhang J; Yang Y; Yang J; Yang W; Hong T
    Int J Clin Pract; 2008 May; 62(5):695-700. PubMed ID: 18412932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The effect of metformin on late diabetic complications and cardiovascular events in obese patients with type 2 diabetes].
    Christiansen AL; Madsbad S
    Ugeskr Laeger; 2002 Apr; 164(15):2022-4. PubMed ID: 11984999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early and intensive therapy for management of hyperglycemia and cardiovascular risk factors in patients with type 2 diabetes.
    Dailey G
    Clin Ther; 2011 Jun; 33(6):665-78. PubMed ID: 21704233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes.
    Herman GA; Bergman A; Yi B; Kipnes M;
    Curr Med Res Opin; 2006 Oct; 22(10):1939-47. PubMed ID: 17022853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metformin: New Preparations and Nonglycemic Benefits.
    Fujita Y; Inagaki N
    Curr Diab Rep; 2017 Jan; 17(1):5. PubMed ID: 28116648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial.
    De Jager J; Kooy A; Lehert P; Bets D; Wulffelé MG; Teerlink T; Scheffer PG; Schalkwijk CG; Donker AJ; Stehouwer CD
    J Intern Med; 2005 Jan; 257(1):100-9. PubMed ID: 15606381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A fixed-dose combination of pioglitazone and metformin: A promising alternative in metabolic control.
    Seufert J
    Curr Med Res Opin; 2006; 22 Suppl 2():S39-48. PubMed ID: 16914074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.